Janus NW Research · Research Program

Precision Nutrition for Populations Standard Guidelines Miss.

We are pursuing an NIH STTR R41 grant to study whether genomic nutrition guidance moves clinical outcomes in Alaska Native and urban Native American adults with Type 2 diabetes and NAFLD.

The guidelines weren't built for this population. Or this genome.

USDA MyPlate and ADA nutrition guidelines are population-average recommendations. They don't account for the genomic variants that change how nutrients are absorbed, converted, and metabolized — variants that vary significantly across ancestral populations.

Why Alaska Native populations are disproportionately affected

Alaska Native adults develop Type 2 diabetes at 3× the national average. Non-alcoholic fatty liver disease (NAFLD) rates are similarly elevated. Both conditions are driven primarily by nutrition and metabolic dysfunction — yet the nutritional interventions deployed by IHS and ANTHC are generic, not personalized to the individual's biochemistry.

What genomic variants actually change

MTHFR variants reduce folate metabolism by 30–65%. FADS1 variants impair omega-3 conversion from plant sources. TCF7L2 elevates T2DM risk and changes carbohydrate response. PNPLA3 rs738409 is the strongest single genetic predictor of NAFLD and liver fibrosis. Standard guidelines ignore all of this.

The drug–nutrient problem

Omeprazole (PPI) depletes B12, magnesium, and calcium. Metformin depletes B12. SSRIs affect sodium and folate. When a patient carries both a genomic variant and a medication that impair the same nutrient pathway, the clinical effect is compounded — and no existing tool flags this intersection.

Why EHR integration matters

Standalone DTC genomic tools (23andMe, Helix) exist, but none are embedded in the clinical workflow or cross-referenced with the patient's active medication list and live lab values. CareShield closes that gap by running inside the provider's existing EHR via SMART on FHIR.

Phase 1 Feasibility Study — NIH STTR R41

A randomized feasibility study comparing CareShield genomic nutrition guidance to standard dietary counseling in Alaska Native and urban Native American adults with T2DM or NAFLD.

Phase
Phase 1 Feasibility
Randomized, controlled. CareShield guidance vs. standard dietary counseling.
Sample Size
n = 40–60
Powered for feasibility signal, not Phase 2 efficacy. Recruitment across two sites.
Duration
12 months
Baseline, 3-month, 6-month, and 12-month follow-up assessments.
Population
AI/AN Adults
Alaska Native adults with T2DM or NAFLD (ANMC) + urban Native American students and community members (Haskell HINU).
Site 1
ANMC, Anchorage
Alaska Native Medical Center. ANTHC-operated. Primary referral hospital for Alaska Native people.
Site 2
Haskell HINU
Haskell Indian Nations University IHS clinic, Lawrence KS. 100% Native American student body. Urban Native population.
Outcome Measure Timepoint Type
Glycemic control Hemoglobin A1C (%) Baseline, 3mo, 6mo, 12mo Primary
Liver health ALT, AST (U/L) Baseline, 6mo, 12mo Primary
Metabolic markers BMI, waist circumference, lipid panel Baseline, 6mo, 12mo Secondary
Dietary adherence Patient-reported 24hr recall + food frequency questionnaire Baseline, 3mo, 6mo, 12mo Secondary
Provider adoption CareShield MPage utilization rate per encounter Throughout Secondary

Building the network. One introduction at a time.

STTR requires ≥30% of funded work at a research institution. We are actively establishing the institutional partner network ahead of the September 8, 2026 deadline.

Active

Julia Rogers & ANTHC

Alaska Native Tribal Health Consortium · Anchorage, AK

Primary research institution candidate. Julia Rogers, recent hire at ANTHC, is our target contact for the institutional PI role. ANTHC also operates a Liver Disease and Hepatitis program — directly aligned with the NAFLD arm of the study.

Role: Institutional PI (30% FTE) · Patient recruitment · IRB · Outcome measurement
Active

Dr. Jason Burkhead, Ph.D.

Institute of Arctic Biology, University of Alaska Fairbanks · Alaska INBRE

Professor and Alaska INBRE Principal Investigator. Advising on bioinformatics and precision medicine. Has offered to help identify UAA/UAF health disparities researchers and facilitate introductions to ANTHC partners.

Role: Scientific advisor · Bioinformatics · Partnership facilitation
In Discussion

Haskell Indian Nations University

Lawrence, KS · 100% Native American enrollment · IHS clinic on campus

Sponsored Programs office identified as the entry point. Prior NIH research partnerships with KU Medical Center. IHS clinic provides clinical access to an urban Native American population distinct from the Alaska Native cohort — expanding the study's generalizability.

Role: Secondary clinical site · Urban Native American recruitment · IHS clinic access
In Discussion

KU Medical Center

University of Kansas Medical Center · Kansas City, KS · CTSA NIH funded

45 minutes from Haskell HINU. CTSA (Clinical and Translational Science Award) from NIH. Native health disparities research capacity. Potential co-investigator support for the urban Native American arm of the study.

Role: CTSA support · Co-investigator · Urban Native American research capacity

NIH STTR R41 — Small Business Technology Transfer.

The STTR mechanism funds collaborative research between a small business and a research institution. Phase 1 establishes feasibility and proof-of-concept.

NIH STTR R41 Application

NHGRI · Genomics, Health Disparities, Precision Medicine

Deadline Sept 8, 2026
Funding Institute
NHGRI
National Human Genome Research Institute
Phase 1 Maximum
$400K
Direct costs · 1 year
Company PI
Isabella January
Janus NW Research LLC · UMKC Biology
Institution PI
TBD
≥30% FTE required · ANTHC preferred
Study Section
ZRG1 SBIB-B
Small Business: Informatics, Biotech & Bioinformatics
Phase 2 Path
Up to $2M
Contingent on Phase 1 feasibility outcomes

What we still need

An institutional PI at ≥30% FTE from a qualifying research institution (ANTHC, UAF, KUMC, or Haskell HINU). This is the single blocking item between the current state and a complete application. If you are a researcher in Native health disparities, genomics, clinical informatics, or hepatology — we want to talk.

We are actively recruiting a research institution PI.

If you are a faculty member or staff researcher at an IHS-affiliated institution, tribal health consortium, or university with Native health research capacity — and this study aligns with your work — we want to talk before September 2026.